Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis.

Chen, Lily; Hsi, Andy C; Kothari, Alok; Dehner, Louis P; Hayashi, Robert J; Coughlin, Carrie C

Chen, Lily; Hsi, Andy C; Kothari, Alok; Dehner, Louis P; Hayashi, Robert J; Coughlin, Carrie C.

Afiliação

Chen L; School of Medicine, Washington University, St. Louis, Missouri.
Hsi AC; Department of Pathology, California Skin Institute, San Jose, California.
Kothari A; Lauren V. Ackerman Laboratory of Surgical Pathology and Dermatopathology Center, St. Louis Children's Hospital, Washington University Medical Center, St. Louis, Missouri.
Dehner LP; Division of Hematology/Oncology, Department of Pediatrics, School of Medicine, Washington University, St. Louis, Missouri.
Hayashi RJ; Lauren V. Ackerman Laboratory of Surgical Pathology and Dermatopathology Center, St. Louis Children's Hospital, Washington University Medical Center, St. Louis, Missouri.
Coughlin CC; Division of Hematology/Oncology, Department of Pediatrics, School of Medicine, Washington University, St. Louis, Missouri.

Pediatr Dermatol ; 35(6): e402-e403, 2018 Nov.

Article em En | MEDLINE | ID: mdl-30216522

ABSTRACT

ABSTRACT

We present a 3-year-old boy with Langerhans cell histiocytosis who developed granulomatous dermatitis while taking vemurafenib. Vemurafenib currently has Food and Drug Administration approval for the treatment of BRAF V600E+ metastatic melanoma in adults, but recent discoveries of BRAF V600E in more than half of tested Langerhans cell histiocytosis lesions have prompted clinical trials of vemurafenib therapy for children with refractory, multisystem Langerhans cell histiocytosis. This report contributes to the knowledge of its potential side effects when used in children.

Assuntos

Antineoplásicos/efeitos adversos; Toxidermias/diagnóstico; Histiocitose de Células de Langerhans/tratamento farmacológico; Indóis/efeitos adversos; Sulfonamidas/efeitos adversos; Pré-Escolar; Toxidermias/tratamento farmacológico; Toxidermias/etiologia; Glucocorticoides/uso terapêutico; Granuloma/etiologia; Humanos; Masculino; Pele/patologia; Triancinolona/uso terapêutico; Vemurafenib

Palavras-chave

BRAF inhibitor; granulomatous dermatitis; pediatric; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulfonamidas / Histiocitose de Células de Langerhans / Toxidermias / Indóis / Antineoplásicos Tipo de estudo: Etiology_studies Limite: Child, preschool / Humans / Male Idioma: En Revista: Pediatr Dermatol Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google